‘Mistakes were made’: Monks’ performance under scrutiny as tariffs wipe out gains

Monks' board will examine stock-specific mistakes made by Baillie Gifford trio Spencer Adair, Malcolm MacColl and Helen Xiong after five years of disappointing performance.

Monks’ (MNKS ) board has promised to scrutinise stock-specific errors that were made by Baillie Gifford managers Spencer Adair, Malcolm MacColl and Helen Xiong, following another year of disappointing performance. 

The £2.4bn global equity trust grew its net asset value (NAV) by only 0.1% over the year to the end of April, which compares to a 5.3% rise by the FTSE World index.

The trust also lagged the index over five years, something the board’s chair Karl Sternberg said would warrant closer examination.

‘Given that we are behind the index over five years, you can expect the board to be considering this issue in even greater detail,’ Sternberg explained.

He noted that the index has been difficult for active managers to beat, not least Monks. Although it owned most of the companies that have driven stock market returns in recent years, these stocks represented a smaller proportion of Monks’ portfolio than their index weightings. 

‘Nevertheless, our team has made mistakes, as every team makes mistakes,’ Sternberg aknowledged.

‘I have referred in the past to the importance of refocusing on valuations; and there have (inevitably) been stock-specific errors. The board’s role is to be constructively critical, to probe more deeply when things are going well, and to be more supportive during more difficult periods.’

Monks continues to trade at a discount, currently 9%. As Sternberg believes it is the board’s ‘obligation to be ready buyers at a discount’, the trust repurchased 26.5m at a cost of £321m over the year. This represented 27.7% of the company’s shares and one of the largest buybacks in the global equity sector.

The buybacks will continue as Sternberg said there was a ‘clearer investor preference for lower and less volatile discounts’.

‘That is what you should expect to see in future at Monks,’ he said.

‘We are reluctant to have a zero discount policy, effectively giving up the advantages of not being open-ended. However, the board believes that shareholders should expect the company to attempt to restrict any discount to net asset value with borrowings calculated at fair value, to mid-single digits, in normal market conditions.’

Tariff turmoil

In a frustrating twist, Monks’ performance had been ahead of the market over the first 10 months of its financial year, with the NAV close to an all-time high of £15.00 in February. This was before US president Donald Trump’s ‘Liberation Day’ tariff announcements, which caused havoc in global markets and wiped out gains made by the global equity trust.

The portfolio couldn’t withstand the sharp sell-off in the US, which makes up its largest geographic weighting at around two thirds of the fund. Volatility created by tariffs was compounded by a lack of clarity on how the US budget deficit will be brought under control.

While global geopolitics is likely to lead to more fractious global trade and a wider range of outcomes for investors, Monks’ management trio expects the trust’s bias towards ‘higher growth and higher quality’ to pay off.

Closer to home, Trump’s decision to appoint vaccine sceptic Robert F. Kennedy as health secretary also affected the trust. It sparked share price falls in two of Monks’ holdings: pharmaceutical giant Novo Nordisk and Elevance, the second biggest health insurer in the US.

The latter also suffered from ‘the number of government-supported Medicaid customers falling as eligibility criteria are tightened post-pandemic’. However, looking ahead the managers said the ‘growing need for health insurance coverage – as the population ages and treatment becomes more expensive – provides a structural tailwind for growth in the years ahead’.

Novo Nordisk was impacted by disappointing trials from its latest weight loss injection CagriSema. Nonetheless, the managers described the share price sell-off as ‘overdone’.

‘Today, just over 10 million people take obesity drugs globally, only 1% of the global obese population. As supply constraints ease, we expect this number to expand significantly,’ they said.

‘As a leader in the field of diabetes and metabolic disease, we expect Novo to continue to garner a significant share of the obesity market and believe the company has an underappreciated competitive advantage in manufacturing that is difficult and costly to replicate.’

Adair, MacColl and Xiong sold out of Moderna after revenue from its Covid vaccine disappointed and it was slow in bringing a new respiratory syncytial virus drug to market, allowing competitors to ‘steal the lead’.

‘Though we continue to believe that they have a potentially exciting pipeline of drugs, our patience has been exhausted,’ said the manager.

Some profits were also taken in Alnylam Pharmaceuticals after positive results from its late-stage trial to treat a rare heart condition, that could multiply its addressable patient population 10-fold.

‘We took some profits on shareholders’ behalf after the share price rose by 80%, but we remain excited by the company’s potential to address even larger patient populations,’ they said.

Over the past five years, Monks’ shares are up 23.9% which compares to 42.2% by the average trust in the AIC’s global sector.